<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href='static/style.xsl' type='text/xsl'?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T08:43:53Z</responseDate><request verb="GetRecord" identifier="oai:ecommons.cornell.edu:1813/59083" metadataPrefix="dim">https://ecommons.cornell.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:ecommons.cornell.edu:1813/59083</identifier><datestamp>2026-05-15T19:50:21Z</datestamp><setSpec>com_1813_35</setSpec><setSpec>col_1813_47</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author">Jing, Hui</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="chair">Lin, Hening</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember">Cerione, Richard A.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember">Weiss, Robert S.</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2018-10-03T19:27:40Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2019-12-18T07:00:45Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2017-12-30</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Submission ID: 10577</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Publication ID: 10637500</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/1813/59083</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="doi">https://doi.org/10.7298/X4DB800G</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="bibid">10474186</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">SIRT2 belongs to the mammalian sirtuin or NAD-dependent lysine deacylase family. Growing evidence suggests that SIRT2 plays important roles in cell cycle regulation, stress response, metabolism and differentiation by deacetylating a wide variety of substrates. Targeting SIRT2 for cancer treatment has been a topic of debate due to conflicting reports and lack of potent and specific inhibitors. 
I began the project with the development and mechanistic study of SIRT2 inhibitors. From a collection of mechanism-based small molecule inhibitors mimicking different lysine acyl modifications, I characterized that a thiomyristoyl lysine compound (TM), a potent SIRT2-specific inhibitor, has broad anticancer effect in various human cancer cells and mouse models of breast cancer. Mechanistically, I demonstrated that SIRT2 inhibition promotes c-Myc ubiquitination and degradation and that the anticancer effect of TM correlates with its ability to decrease c-Myc level. This study suggests that SIRT2 inhibition could be utilized to target c-Myc and that potent and selective SIRT2 inhibitors are promising anticancer agents.
SIRT2 has been reported to have lysine defatty-acylase activity in addition to the previously known deacetylase activity. However, whether the defatty-acylase activity is physiologically relevant has not been investigated. I identified the oncoprotein K-Ras4a as a SIRT2 defatty-acylase substrate. I further elucidated that SIRT2-mediated lysine defatty-acylation promotes endomembrane localizaiton of K-Ras4a, enhances its interaction with A-Raf, and thus promotes cellular transformation. This study not only highlights lysine fatty acylation as a previously unknown regulatory mechanism for the Ras family of GTPases that is distinct from cysteine fatty acylation, but also unveils a new mechanism by which SIRT2 is involved in cancer by defatty-acylating K-Ras4a. This finding also provides further support that SIRT2 is a promising target for cancer treatment.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en_US</dim:field>
   <dim:field mdschema="dc" element="rights" lang="*">Attribution-NonCommercial-NoDerivatives 4.0 International</dim:field>
   <dim:field mdschema="dc" element="rights" qualifier="uri" lang="*">https://creativecommons.org/licenses/by-nc-nd/4.0/</dim:field>
   <dim:field mdschema="dc" element="subject">c-Myc</dim:field>
   <dim:field mdschema="dc" element="subject">K-Ras</dim:field>
   <dim:field mdschema="dc" element="subject">Lysine fatty acylation</dim:field>
   <dim:field mdschema="dc" element="subject">SIRT2</dim:field>
   <dim:field mdschema="dc" element="subject">Sirtuin</dim:field>
   <dim:field mdschema="dc" element="subject">Chemistry</dim:field>
   <dim:field mdschema="dc" element="subject">cancer</dim:field>
   <dim:field mdschema="dc" element="title">MULTIPLE ENZYMATIC FUNCTIONS OF SIRT2 AND ITS INVOLVEMENT IN CANCER</dim:field>
   <dim:field mdschema="dc" element="type">dissertation or thesis</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="discipline">Chemistry and Chemical Biology</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="grantor">Cornell University</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="level">Doctor of Philosophy</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="name">Ph. D., Chemistry and Chemical Biology</dim:field>
   <dim:field mdschema="dcterms" element="license">https://hdl.handle.net/1813/59810</dim:field>
   <dim:field mdschema="dspace" element="entity" qualifier="type">Publication</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="collection" authority="https://cornell-ecommons.eks.prod.4science.cloud/handle/1813/47" confidence="600">Cornell Theses and Dissertations</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="author">Jing, Hui</dim:field>
   <dim:field mdschema="cris" element="virtualsource" qualifier="collection">5893a6ea-7af3-41d7-abc6-04bcd26ab5df</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="cerif" element="openaire" authority="" confidence="-1">&lt;Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="492cec32-620a-4ccc-abd0-66f8fb6df55f">
	&lt;Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843&lt;/Type>
	&lt;Language>en_US&lt;/Language>
   	&lt;Title>MULTIPLE ENZYMATIC FUNCTIONS OF SIRT2 AND ITS INVOLVEMENT IN CANCER&lt;/Title>
   	&lt;PublishedIn>
    	&lt;Publication>
      	&lt;/Publication>
   	&lt;/PublishedIn>
   	&lt;PublicationDate>2017-12-30&lt;/PublicationDate>
   	&lt;DOI>https://doi.org/10.7298/X4DB800G&lt;/DOI>
   	&lt;Authors>
      	&lt;Author>
        	&lt;DisplayName>Jing, Hui&lt;/DisplayName>
         	&lt;Affiliation>
         		&lt;OrgUnit>
         		&lt;/OrgUnit>
         	&lt;/Affiliation>
      	&lt;/Author>
	&lt;/Authors>
   	&lt;Editors>
	&lt;/Editors>
    &lt;Publishers>
        &lt;Publisher>
            &lt;OrgUnit />
        &lt;/Publisher>
    &lt;/Publishers>
    &lt;License>https://creativecommons.org/licenses/by-nc-nd/4.0/&lt;/License>
    &lt;Keyword>c-Myc&lt;/Keyword>
    &lt;Keyword>K-Ras&lt;/Keyword>
    &lt;Keyword>Lysine fatty acylation&lt;/Keyword>
    &lt;Keyword>SIRT2&lt;/Keyword>
    &lt;Keyword>Sirtuin&lt;/Keyword>
    &lt;Keyword>Chemistry&lt;/Keyword>
    &lt;Keyword>cancer&lt;/Keyword>
   	&lt;Abstract>SIRT2 belongs to the mammalian sirtuin or NAD-dependent lysine deacylase family. Growing evidence suggests that SIRT2 plays important roles in cell cycle regulation, stress response, metabolism and differentiation by deacetylating a wide variety of substrates. Targeting SIRT2 for cancer treatment has been a topic of debate due to conflicting reports and lack of potent and specific inhibitors. 
I began the project with the development and mechanistic study of SIRT2 inhibitors. From a collection of mechanism-based small molecule inhibitors mimicking different lysine acyl modifications, I characterized that a thiomyristoyl lysine compound (TM), a potent SIRT2-specific inhibitor, has broad anticancer effect in various human cancer cells and mouse models of breast cancer. Mechanistically, I demonstrated that SIRT2 inhibition promotes c-Myc ubiquitination and degradation and that the anticancer effect of TM correlates with its ability to decrease c-Myc level. This study suggests that SIRT2 inhibition could be utilized to target c-Myc and that potent and selective SIRT2 inhibitors are promising anticancer agents.
SIRT2 has been reported to have lysine defatty-acylase activity in addition to the previously known deacetylase activity. However, whether the defatty-acylase activity is physiologically relevant has not been investigated. I identified the oncoprotein K-Ras4a as a SIRT2 defatty-acylase substrate. I further elucidated that SIRT2-mediated lysine defatty-acylation promotes endomembrane localizaiton of K-Ras4a, enhances its interaction with A-Raf, and thus promotes cellular transformation. This study not only highlights lysine fatty acylation as a previously unknown regulatory mechanism for the Ras family of GTPases that is distinct from cysteine fatty acylation, but also unveils a new mechanism by which SIRT2 is involved in cancer by defatty-acylating K-Ras4a. This finding also provides further support that SIRT2 is a promising target for cancer treatment.&lt;/Abstract>
	&lt;Access xmlns="http://purl.org/coar/access_right" 
    >
    &lt;/Access>
&lt;/Publication>
</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>